Overview

• U.S. life science tools provider's Q1 sales were flat but beat analyst expectations

• Adjusted EPS for Q1 beat analyst expectations

• Company reaffirmed full-year 2026 guidance

Outlook

• Avantor reaffirms its full-year 2026 financial guidance provided in February 2026

Result Drivers

• BIOSCIENCE & MEDTECH EXECUTION - Co said improved execution in Bioscience and Medtech Products contributed to Q1 results

• VWR STABILIZATION - Co said it saw stabilization in VWR Distribution & Services segment

• REVIVAL INITIATIVE - CEO said Revival initiative is having a positive impact and driving momentum

Company press release: ID:nPn5TxxC4a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Sales	Beat	$1.58 bln	$1.54 bln (14 Analysts)
Q1 Adjusted EPS	Beat	$0.17	$0.16 (16 Analysts)
Q1 Net Income		$43.30 mln
Q1 Gross Profit		$500.70 mln
Q1 Operating Income		$99.50 mln
Q1 Pretax Profit		$55.50 mln

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and 3 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• Wall Street's median 12-month price target for Avantor Inc is $10.00, about 27.2% above its April 28 closing price of $7.86

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.